CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 105 enrolled
Drug / intervention
Rivaroxaban 10 MGdrug
Likely dose
Rivaroxaban 10 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03506815
NCT03506815Phase 3Completed
CompareCT.gov

A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis With Rivaroxaban in Patients With Malignancy and Central Venous Catheters

Ottawa Hospital Research Institute·interventional·Posted Apr 24, 2018·Updated Jul 5, 2024

In Brief

A Phase 3 clinical trial evaluating Rivaroxaban 10 MG for Upper Extremity Deep Vein Thrombosis and 2 related conditions. Completed, enrolled 105 participants across 1 site.

Detailed Summary

Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated venous thromboembolism (VTE) among cancer patients. Hypothesis: treatment with low dose rivaroxaban (10mg) will reduce the incidence of upper extremity venous thrombosis in a high risk population with cancer and CVC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer
CountriesCanada
CollaboratorsQueen Elizabeth II Health Sciences Centre, University of Alberta, Hamilton Health Sciences Corporation

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 24, 2018
Enrollment StartMar 15, 2019
Primary CompletionMay 14, 2020
Study CompletionJun 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.2 years ago

Interventions

Rivaroxaban 10 MGdrug

Rivaroxaban 10mg po daily x 90 (+/- 3 days)